drugset
drugset / Trial / NCT04979910

Targeting IL-17A for Treatment-Resistant Depression

NCT04979910 ↗

Phase 2 Completed 7 enrolled Icahn School of Medicine at Mount Sinai
NaSingle-groupOpen-labelTreatment

Summary

The proposed study aims to test ixekizumab, a monoclonal antibody (mAb) against interleukin 17A (IL-17A), in patients with treatment-resistant depression (TRD).

Timeline

Start
2021-08-27
Primary completion
2024-04-12
Completion
2024-04-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ixekizumab Monoclonal antibody 80 mg Subcutaneous

Indications

major depressive disorder